Michael R. Lewis, PhD

University of Missouri – Columbia (MU)

Dr. Lewis is considered to be an expert in tumor biology, radiopharmaceutical chemistry, development of laboratory animal models of cancer, and non-invasive imaging of veterinary patients. Dr. Lewis has considerable experience in radiopharmaceutical development, including radionuclide production and purification, radiolabeling of biomolecular tumor-targeting vectors, and in vitro and in vivo evaluation of radiopharmaceuticals. His recent research has focused on the development of radiolabeled antibodies, peptides, and peptide nucleic acids for binding cell surface receptors and oncogene products with high affinity and specificity, for targeted imaging and therapy of cancer. These biomolecules have been labeled with various radionuclides, including 99mTc, 111In, 90Y, 64Cu, 67Cu, 57Co, 66Ga, 86Y, 45Ti, 177Lu, 166Ho, 149Pm, and 153Sm.